[Skip to Navigation]
October 1997

Topical 2.0% Dorzolamide vs Oral Acetazolamide for Prevention of Intraocular Pressure Rise After Neodymium:YAG Laser Posterior Capsulotomy

Author Affiliations

From the Department of Ophthalmology, Athens University School of Medicine, Athens, Greece.

Arch Ophthalmol. 1997;115(10):1241-1244. doi:10.1001/archopht.1997.01100160411003

Objective:  To compare the efficacy and safety of topical 2.0% dorzolamide hydrochloride with oral acetazolamide in preventing intraocular pressure (IOP) rise following neodymium:YAG (Nd:YAG) laser posterior capsulotomy.

Design:  A prospective, randomized, double-masked, placebo-controlled study.

Patients:  Two hundred ten patients undergoing Nd: YAG laser posterior capsulotomy.

Intervention:  Pretreatment with dorzolamide, acetazolamide, or placebo. Dorzolamide administration as a single drop (1 drop≈20 μL) 1 hour before capsulotomy. Acetazolamide administration as a single dose of 125 mg orally 1 hour before capsulotomy.

Results:  At first and third hour postoperatively, IOPs and IOP changes from baseline were significantly (P<.001) higher in the placebo group than in the dorzolamide or acetazolamide group. At the same time, IOPs and IOP changes from baseline were similar (P>.50) in the dorzolamide and acetazolamide groups. No patient treated with dorzolamide or acetazolamide experienced an IOP higher than 30 mm Hg after capsulotomy, but 15.7% of patients receiving placebo had an IOP above this level (P<.001). Of patients receiving placebo, 5.7% experienced IOP higher than 35 mm Hg. No serious side effects were recorded in any of the studied patients.

Conclusion:  Topical 2.0% dorzolamide and oral acetazolamide, given prophylactically as a single administration 1 hour before Nd:YAG laser posterior capsulotomy, have comparable high efficacy and safety in preventing IOP elevation following this procedure.

Add or change institution